Maverick’s growth from ₹14 crore to ₹136 crore in revenue shows real demand, backed by rising medical seats and NMC’s mandatory skills labs. But the Voxel-Man deal is a related party transaction, with the founder on both sides and no disclosed revenue for the target. New investors get anti-dilution protection that other shareholders don’t, so is this a smart strategic move or one that needs closer scrutiny?
Maverick Simulation: ₹125 Cr Fundraise & ₹260 Cr Voxel-Man Deal
Delhi-based medical simulator maker Maverick is raising ₹125 crore from Paragon, VantEdge and Inviga, while acquiring Swiss surgical-simulator firm Voxel-Man for ₹260 crore in shares. The catch: Voxel-Man is 100% owned by Maverick’s own founder. We break down the deal, the valuation and what shareholders should ask before voting.